FY2020 · ended Dec 31, 2020 · Revenue $2.01M, -69.3% YoY · Filed Mar 23, 2022
Cocrystal Pharma, Inc. (COCP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$8.2 million. As of Jun 30, 2026 it held $2.2 million in cash and investments and $1.3 million in total debt.
Revenue
$2.01M
-69.3% vs prior year
Net income (TTM)
$-9.94M
+20.9% vs year-ago TTM
Operating cash flow (TTM)
$-7.95M
+40.5% vs year-ago TTM
Free cash flow
$-8.20M
+50.3% vs prior year
EPS (TTM)
$-0.76
+38.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
13.79M
+35.5% vs prior year
Net cash
$827,000
as of Jun 30, 2026
Operating margin
-476.0%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COCP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1412486
- Former names
- BIOZONE PHARMACEUTICALS, INC. (until Mar 25, 2014); International Surf Resorts, Inc. (until Mar 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M | -$14.2M |
| Net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M | -$14.2M |
| Diluted EPS | -$0.78 | -$1.72 | -$1.87 | — | — |
| Operating cash flow | -$8.2M | -$16.5M | -$14.7M | -$21.4M | -$12.7M |
| Free cash flow | -$8.2M | -$16.5M | -$14.8M | -$21.5M | -$12.8M |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M |
| Stockholders' equity | $6.3M | $9.5M | $26.4M | $39.6M | $77.5M |
| Cash and investments | $7.0M | $9.9M | $26.4M | $37.1M | $58.7M |
| Total debt | $1.5M | $1.8M | $1.9M | $297,000 | $534,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 18, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 3, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 17, 2026 | Jul 14, 2026 |
All 672 Cocrystal Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.